Advanced Filters
noise

pulmonary-arterial-hypertension Clinical Trials

A listing of pulmonary-arterial-hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 82 clinical trials
H Hilde J Bjørkekjær, MD

Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis

The goal of this observational pilot trial is to evaluate the feasibility of home monitoring for patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). The study will assess home-based measures that may help detect disease progression earlier and will also evaluate patient satisfaction, usability, and the impact on health-related quality …

18 years of age All Phase N/A
L Laurent Savale, MD

COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

Pulmonary arterial hypertension (PAH) is a rare, progressive disease associated with poor prognosis, especially in patients with cardiovascular comorbidities. Current guidelines recommend initial combination therapy, but evidence is lacking for patients with significant comorbidities who are often excluded from clinical trials. The COMMODITIES trial is a multicenter, randomized, controlled study …

18 years of age All Phase 3
S Shaoliang Chen, MD

Real-World Study of PADN for the Treatment of PAH

Real-World Study of PADN for the Treatment of PAH

years of age All Phase N/A
L Laurie Hogl

Repurposing Valsartan May Protect Against Pulmonary Hypertension

This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.

18 - 80 years of age All Phase 2
周胜男

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH) receive CD19-BCMA CAR T cell therapy. The primary objective is to prospectively assess the safety of CD19-BCMA CAR T cell therapy in …

10 - 65 years of age All Phase 1/2

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.

This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH receive umbilical cord blood CD19-BCMA CAR T cell therapy. The primary objective is to prospectively assess the safety of umbilical cord blood …

6 - 65 years of age All Phase 1/2

A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia

In this study, the investigators will follow two small cohorts of pregnant women: a cohort of healthy women with uncomplicated pregnancies residing at high altitude, a control group of healthy women with uncomplicated pregnancies residing at sea level, to characterize differences in cardiopulmonary adaptation and nitric oxide (NO) pathway expression …

18 - 45 years of age Female Phase N/A
R Russell Richardson, Ph.D.

: Vascular Function in Health and Disease

Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively …

18 years of age All Phase 1
L Luigi R Boccardi, BS

Pulmonary Hypertension Biorepository and Registry

Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.

18 years of age All Phase N/A
D David Ptashnik, MS

Pulmonary Hypertension SOLAR

The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in …

18 years of age All Phase 2

Simplify language using AI